Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells
- 1 October 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 348 (4) , 1245-1253
- https://doi.org/10.1016/j.bbrc.2006.07.185
Abstract
No abstract availableKeywords
Funding Information
- National Pancreas Foundation
This publication has 24 references indexed in Scilit:
- Maturation-dependent oligodendrocyte apoptosis caused by hyperoxiaJournal of Neuroscience Research, 2006
- Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cellsCarcinogenesis: Integrative Cancer Research, 2006
- PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II studyAnnals of Oncology, 2005
- Impact of gemcitabine on the treatment of metastatic pancreatic cancerJournal of Gastroenterology and Hepatology, 2005
- Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II StudyCancer Investigation, 2005
- Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κBMolecular Cell, 2004
- The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571Blood, 2003
- Pancreatic cancer biology and geneticsNature Reviews Cancer, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Disruption of Hsp90 Function Results in Degradation of the Death Domain Kinase, Receptor-interacting Protein (RIP), and Blockage of Tumor Necrosis Factor-induced Nuclear Factor-κB ActivationJournal of Biological Chemistry, 2000